Global Benign Prostatic Hyperplasia Treatment Market
Global Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Comprehensive Study by Type (Medications (Alpha-blockers, 5-alpha reductase inhibitors, Combination drug therapy and Tadalafil (Cialis)), Minimally invasive or surgical therapy, Laser therapy, Embolization, Others), End-user (Hospitals, Clinics, Ambulatory Surgical Centres), Diagnosis (Digital Rectal Exam, Urine Test, Blood Test, Prostate-Specific Antigen (PSA) Blood Test) Players and Region - Global Market Outlook to 2026

Benign Prostatic Hyperplasia Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 239 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Benign Prostatic Hyperplasia Treatment Market?

Benign prostatic hyperplasia (BPH) is a prostate gland enlargement causing uncomfortable urinary symptoms, such as blocking the flow of urine out of the bladder. It may also cause bladder, urinary tract, or kidney-related issues. Benign prostatic hyperplasia is a common problem that affects the quality of life in approximately one-third of men older than 50 years. It is estimated that around 30 million men have symptoms related to BPH. There are numerous effective treatments available for BPH such as medications, minimally invasive therapies, and surgery. BPH treatment depends upon the size of the prostate, age, overall health, and amount of discomfort.

The market study is being classified by Type (Medications (Alpha-blockers, 5-alpha reductase inhibitors, Combination drug therapy and Tadalafil (Cialis)), Minimally invasive or surgical therapy, Laser therapy, Embolization and Others) and major geographies with country level break-up.

GlaxoSmithKline plc (United Kingdom), Pfizer, Inc. (United States), Abbott (United States), Boston Scientific Corporation (United States), Allergan plc (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Asahi Kasei Corporation (Japan), Boehringer Ingelheim (Germany), Astellas Pharma, Inc. (Japan), Sanofi S.A. (France), Merck & Co., Inc. (United States) and Olympus Corporation (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Teleflex Incorporated (United States) and Endo International plc (Ireland).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Benign Prostatic Hyperplasia Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Benign Prostatic Hyperplasia Treatment market by Type, Application and Region.

On the basis of geography, the market of Benign Prostatic Hyperplasia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Benign Prostatic Hyperplasia
  • Rise in the Number of Hospitals and Clinics

Market Trend
  • Technological Advancements in The Medical Science

Restraints
  • Less Awareness about Benign Prostatic Hyperplasia Treatment among People

Opportunities
  • Growing Geriatric Population Worldwide
  • Growth in the Healthcare Industry Worldwide

Challenges
  • Lack of Healthcare Infrastructure in Underdeveloped Countries


Market Leaders and some development strategies
In June 2019, Pfizer Inc. and Array BioPharma Inc. had announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.



Key Target Audience
Benign Prostatic Hyperplasia Treatment Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Medications (Alpha-blockers, 5-alpha reductase inhibitors, Combination drug therapy and Tadalafil (Cialis))
  • Minimally invasive or surgical therapy
  • Laser therapy
  • Embolization
  • Others
By End-user
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres

By Diagnosis
  • Digital Rectal Exam
  • Urine Test
  • Blood Test
  • Prostate-Specific Antigen (PSA) Blood Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Benign Prostatic Hyperplasia
      • 3.2.2. Rise in the Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Infrastructure in Underdeveloped Countries
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in The Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Benign Prostatic Hyperplasia Treatment, by Type, End-user, Diagnosis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Benign Prostatic Hyperplasia Treatment (Value)
      • 5.2.1. Global Benign Prostatic Hyperplasia Treatment by: Type (Value)
        • 5.2.1.1. Medications (Alpha-blockers, 5-alpha reductase inhibitors, Combination drug therapy and Tadalafil (Cialis))
        • 5.2.1.2. Minimally invasive or surgical therapy
        • 5.2.1.3. Laser therapy
        • 5.2.1.4. Embolization
        • 5.2.1.5. Others
      • 5.2.2. Global Benign Prostatic Hyperplasia Treatment by: End-user (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centres
      • 5.2.3. Global Benign Prostatic Hyperplasia Treatment by: Diagnosis (Value)
        • 5.2.3.1. Digital Rectal Exam
        • 5.2.3.2. Urine Test
        • 5.2.3.3. Blood Test
        • 5.2.3.4. Prostate-Specific Antigen (PSA) Blood Test
      • 5.2.4. Global Benign Prostatic Hyperplasia Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Benign Prostatic Hyperplasia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boston Scientific Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Asahi Kasei Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boehringer Ingelheim (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Astellas Pharma, Inc. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck & Co., Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Olympus Corporation (Japan)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Benign Prostatic Hyperplasia Treatment Sale, by Type, End-user, Diagnosis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Benign Prostatic Hyperplasia Treatment (Value)
      • 7.2.1. Global Benign Prostatic Hyperplasia Treatment by: Type (Value)
        • 7.2.1.1. Medications (Alpha-blockers, 5-alpha reductase inhibitors, Combination drug therapy and Tadalafil (Cialis))
        • 7.2.1.2. Minimally invasive or surgical therapy
        • 7.2.1.3. Laser therapy
        • 7.2.1.4. Embolization
        • 7.2.1.5. Others
      • 7.2.2. Global Benign Prostatic Hyperplasia Treatment by: End-user (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centres
      • 7.2.3. Global Benign Prostatic Hyperplasia Treatment by: Diagnosis (Value)
        • 7.2.3.1. Digital Rectal Exam
        • 7.2.3.2. Urine Test
        • 7.2.3.3. Blood Test
        • 7.2.3.4. Prostate-Specific Antigen (PSA) Blood Test
      • 7.2.4. Global Benign Prostatic Hyperplasia Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Benign Prostatic Hyperplasia Treatment: by Type(USD Million)
  • Table 2. Benign Prostatic Hyperplasia Treatment Medications (Alpha-blockers, 5-alpha reductase inhibitors, Combination drug therapy and Tadalafil (Cialis)) , by Region USD Million (2015-2020)
  • Table 3. Benign Prostatic Hyperplasia Treatment Minimally invasive or surgical therapy , by Region USD Million (2015-2020)
  • Table 4. Benign Prostatic Hyperplasia Treatment Laser therapy , by Region USD Million (2015-2020)
  • Table 5. Benign Prostatic Hyperplasia Treatment Embolization , by Region USD Million (2015-2020)
  • Table 6. Benign Prostatic Hyperplasia Treatment Others , by Region USD Million (2015-2020)
  • Table 7. Benign Prostatic Hyperplasia Treatment: by End-user(USD Million)
  • Table 8. Benign Prostatic Hyperplasia Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 9. Benign Prostatic Hyperplasia Treatment Clinics , by Region USD Million (2015-2020)
  • Table 10. Benign Prostatic Hyperplasia Treatment Ambulatory Surgical Centres , by Region USD Million (2015-2020)
  • Table 11. Benign Prostatic Hyperplasia Treatment: by Diagnosis(USD Million)
  • Table 12. Benign Prostatic Hyperplasia Treatment Digital Rectal Exam , by Region USD Million (2015-2020)
  • Table 13. Benign Prostatic Hyperplasia Treatment Urine Test , by Region USD Million (2015-2020)
  • Table 14. Benign Prostatic Hyperplasia Treatment Blood Test , by Region USD Million (2015-2020)
  • Table 15. Benign Prostatic Hyperplasia Treatment Prostate-Specific Antigen (PSA) Blood Test , by Region USD Million (2015-2020)
  • Table 16. South America Benign Prostatic Hyperplasia Treatment, by Country USD Million (2015-2020)
  • Table 17. South America Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 18. South America Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 19. South America Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 20. Brazil Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 21. Brazil Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 22. Brazil Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 23. Argentina Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 24. Argentina Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 25. Argentina Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 26. Rest of South America Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 28. Rest of South America Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 29. Asia Pacific Benign Prostatic Hyperplasia Treatment, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 32. Asia Pacific Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 33. China Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 34. China Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 35. China Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 36. Japan Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 37. Japan Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 38. Japan Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 39. India Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 40. India Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 41. India Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 42. South Korea Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 43. South Korea Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 44. South Korea Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 45. Taiwan Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 46. Taiwan Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 47. Taiwan Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 48. Australia Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 49. Australia Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 50. Australia Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 54. Europe Benign Prostatic Hyperplasia Treatment, by Country USD Million (2015-2020)
  • Table 55. Europe Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 56. Europe Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 57. Europe Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 58. Germany Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 59. Germany Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 60. Germany Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 61. France Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 62. France Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 63. France Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 64. Italy Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 65. Italy Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 66. Italy Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 67. United Kingdom Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 69. United Kingdom Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 70. Netherlands Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 71. Netherlands Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 72. Netherlands Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 73. Rest of Europe Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 75. Rest of Europe Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 76. MEA Benign Prostatic Hyperplasia Treatment, by Country USD Million (2015-2020)
  • Table 77. MEA Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 78. MEA Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 79. MEA Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 80. Middle East Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 81. Middle East Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 82. Middle East Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 83. Africa Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 84. Africa Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 85. Africa Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 86. North America Benign Prostatic Hyperplasia Treatment, by Country USD Million (2015-2020)
  • Table 87. North America Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 88. North America Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 89. North America Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 90. United States Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 91. United States Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 92. United States Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 93. Canada Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 94. Canada Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 95. Canada Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 96. Mexico Benign Prostatic Hyperplasia Treatment, by Type USD Million (2015-2020)
  • Table 97. Mexico Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2015-2020)
  • Table 98. Mexico Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2015-2020)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Benign Prostatic Hyperplasia Treatment: by Type(USD Million)
  • Table 112. Benign Prostatic Hyperplasia Treatment Medications (Alpha-blockers, 5-alpha reductase inhibitors, Combination drug therapy and Tadalafil (Cialis)) , by Region USD Million (2021-2026)
  • Table 113. Benign Prostatic Hyperplasia Treatment Minimally invasive or surgical therapy , by Region USD Million (2021-2026)
  • Table 114. Benign Prostatic Hyperplasia Treatment Laser therapy , by Region USD Million (2021-2026)
  • Table 115. Benign Prostatic Hyperplasia Treatment Embolization , by Region USD Million (2021-2026)
  • Table 116. Benign Prostatic Hyperplasia Treatment Others , by Region USD Million (2021-2026)
  • Table 117. Benign Prostatic Hyperplasia Treatment: by End-user(USD Million)
  • Table 118. Benign Prostatic Hyperplasia Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 119. Benign Prostatic Hyperplasia Treatment Clinics , by Region USD Million (2021-2026)
  • Table 120. Benign Prostatic Hyperplasia Treatment Ambulatory Surgical Centres , by Region USD Million (2021-2026)
  • Table 121. Benign Prostatic Hyperplasia Treatment: by Diagnosis(USD Million)
  • Table 122. Benign Prostatic Hyperplasia Treatment Digital Rectal Exam , by Region USD Million (2021-2026)
  • Table 123. Benign Prostatic Hyperplasia Treatment Urine Test , by Region USD Million (2021-2026)
  • Table 124. Benign Prostatic Hyperplasia Treatment Blood Test , by Region USD Million (2021-2026)
  • Table 125. Benign Prostatic Hyperplasia Treatment Prostate-Specific Antigen (PSA) Blood Test , by Region USD Million (2021-2026)
  • Table 126. South America Benign Prostatic Hyperplasia Treatment, by Country USD Million (2021-2026)
  • Table 127. South America Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 128. South America Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 129. South America Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 130. Brazil Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 131. Brazil Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 132. Brazil Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 133. Argentina Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 134. Argentina Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 135. Argentina Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 136. Rest of South America Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 137. Rest of South America Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 138. Rest of South America Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 139. Asia Pacific Benign Prostatic Hyperplasia Treatment, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 141. Asia Pacific Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 142. Asia Pacific Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 143. China Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 144. China Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 145. China Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 146. Japan Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 147. Japan Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 148. Japan Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 149. India Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 150. India Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 151. India Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 152. South Korea Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 153. South Korea Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 154. South Korea Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 155. Taiwan Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 156. Taiwan Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 157. Taiwan Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 158. Australia Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 159. Australia Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 160. Australia Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 164. Europe Benign Prostatic Hyperplasia Treatment, by Country USD Million (2021-2026)
  • Table 165. Europe Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 166. Europe Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 167. Europe Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 168. Germany Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 169. Germany Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 170. Germany Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 171. France Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 172. France Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 173. France Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 174. Italy Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 175. Italy Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 176. Italy Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 177. United Kingdom Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 178. United Kingdom Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 179. United Kingdom Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 180. Netherlands Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 181. Netherlands Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 182. Netherlands Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 183. Rest of Europe Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 184. Rest of Europe Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 185. Rest of Europe Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 186. MEA Benign Prostatic Hyperplasia Treatment, by Country USD Million (2021-2026)
  • Table 187. MEA Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 188. MEA Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 189. MEA Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 190. Middle East Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 191. Middle East Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 192. Middle East Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 193. Africa Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 194. Africa Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 195. Africa Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 196. North America Benign Prostatic Hyperplasia Treatment, by Country USD Million (2021-2026)
  • Table 197. North America Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 198. North America Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 199. North America Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 200. United States Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 201. United States Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 202. United States Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 203. Canada Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 204. Canada Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 205. Canada Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 206. Mexico Benign Prostatic Hyperplasia Treatment, by Type USD Million (2021-2026)
  • Table 207. Mexico Benign Prostatic Hyperplasia Treatment, by End-user USD Million (2021-2026)
  • Table 208. Mexico Benign Prostatic Hyperplasia Treatment, by Diagnosis USD Million (2021-2026)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Benign Prostatic Hyperplasia Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Benign Prostatic Hyperplasia Treatment: by End-user USD Million (2015-2020)
  • Figure 6. Global Benign Prostatic Hyperplasia Treatment: by Diagnosis USD Million (2015-2020)
  • Figure 7. South America Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 8. Asia Pacific Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 9. Europe Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 10. MEA Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 11. North America Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 12. Global Benign Prostatic Hyperplasia Treatment share by Players 2020 (%)
  • Figure 13. Global Benign Prostatic Hyperplasia Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Benign Prostatic Hyperplasia Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 18. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott (United States) Revenue: by Geography 2020
  • Figure 22. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Boston Scientific Corporation (United States) Revenue: by Geography 2020
  • Figure 24. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 26. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 27. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 28. Asahi Kasei Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Asahi Kasei Corporation (Japan) Revenue: by Geography 2020
  • Figure 30. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 32. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2020
  • Figure 34. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 36. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Olympus Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 39. Olympus Corporation (Japan) Revenue: by Geography 2020
  • Figure 40. Global Benign Prostatic Hyperplasia Treatment: by Type USD Million (2021-2026)
  • Figure 41. Global Benign Prostatic Hyperplasia Treatment: by End-user USD Million (2021-2026)
  • Figure 42. Global Benign Prostatic Hyperplasia Treatment: by Diagnosis USD Million (2021-2026)
  • Figure 43. South America Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 44. Asia Pacific Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 45. Europe Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 46. MEA Benign Prostatic Hyperplasia Treatment Share (%), by Country
  • Figure 47. North America Benign Prostatic Hyperplasia Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline plc (United Kingdom)
  • Pfizer, Inc. (United States)
  • Abbott (United States)
  • Boston Scientific Corporation (United States)
  • Allergan plc (Ireland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Asahi Kasei Corporation (Japan)
  • Boehringer Ingelheim (Germany)
  • Astellas Pharma, Inc. (Japan)
  • Sanofi S.A. (France)
  • Merck & Co., Inc. (United States)
  • Olympus Corporation (Japan)
Additional players considered in the study are as follows:
Teleflex Incorporated (United States) , Endo International plc (Ireland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation